Celyad Oncology Sa · EURONEXT:CYAD

Celyad Oncology Sa — Investor Presentation (January 2023)

15 slides from Celyad Oncology Sa's investor presentation, January 2023

  1. Slide 1: Celyad 2.0: A new era of innovation and maximizing strengths

    Celyad 2.0: A new era of innovation and maximizing strengths Corporate presentation January 2023 1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding beliefs about and expectations for the C

  3. Slide 3: Towards the future for CAR T-cell therapies

    Towards the future for CAR T-cell therapies 3

  4. Slide 4: CAR T-cell market

    CAR T-cell market Allows for numerous partnering and licensing opportunities CAR-Ts are expected to potentially generate substantial market value within the next 5 years $28Bn >$15Bn >30% Estimated global Estimated global Estimated compound annual market size for cell market size of CAR-T growth rat

  5. Slide 5: CAR T-cell market

    CAR T-cell market Adoptive cell therapy development has increased rapidly Key statistics on the CAR T-cell market Number of CAR T-cells per highest 300 phase of development 250 Number of trials 1600 1404 200 Number of Products 1400 150 1200 1000 100 800 600 50 237 400 67 5 3 8 0 200 0 Preclinical Ph

  6. Slide 6: CAR T-cell therapies: main limitations of current approaches

    CAR T-cell therapies 4 main limitations of current CAR T-cell approaches 1. Only two targets demonstrated efficacy and only in 2. Single targeting leads to resistance to treatment and low hematological tumors duration of responses 57% of the CAR T- cells in Phase 2 or above are targeting CD19 3. Aut

  7. Slide 7: Introducing Celyad 2.0

    @& Celyad Introducing Celyad 2.0

  8. Slide 8: Introducing Celyad 2.0

    Introducing Celyad 2.0 We believe cell and gene therapy IP monetization represents a blue ocean for Celyad Celyad has compiled a foundational and broad IP estate that controls key aspects to developing therapies in the allogeneic cell therapy space  Looking Beyond the Typical Clinical Development P

  9. Slide 9: Introducing Celyad 2.0

    Introducing Celyad 2.0 A new era of innovation and maximizing strengths Pursuing a Non-gene Edited Robust Differentiated shRNA-Powered & Intellectual Strategy for CAR Ts TIM Technologies Property Estate ● All-in-one vector approach ● Offers dynamic platform for ● Multiple foundational U.S. the devel

  10. Slide 10: Dual CAR program: Could change the paradigm of cell therapy

    Dual CAR program: Could change the paradigm of cell therapy Pursuing a differentiated strategy for CAR Ts  Overcome resistance and immune escape to single targeting therapies  Move the CAR T-cell landscape beyond B-cell malignancies With a dual CAR, several antigens can be targeted together by the

  11. Slide 11: B7-H6 program: Increasing potential of current CAR Ts

    B7-H6 program: Increasing potential of current CAR Ts Pursuing a differentiated strategy for CAR Ts  Move the CAR T-cell landscape beyond B-cell malignancies  Underestimated target that could change the paradigm of cell therapy Attractive approach to target a broad range of cancers including lymph

  12. Slide 12: shRNA platform: Multiplexing provides broad potential for cell therapies

    shRNA platform: Multiplexing provides broad potential for cell therapies Pursuing a differentiated strategy for CAR Ts  Modulation with shRNA allows targeting of essential functional genes and genes whose partial expression is required  Provides potential for broad therapeutic functionality Multip

  13. Slide 13: How do we address the main limitations of current CAR T-cell approaches?

    How do we address the 4 main limitations of current CAR T-cell approaches? We believe our differentiated strategy will make a difference 1. Only two targets demonstrated efficacy and only in 2. Single targeting leads to resistance to treatment and low hematological tumors duration of responses  Our

  14. Slide 14: Executive summary

    Executive summary Celyad 2.0 business model will prioritize discovery research and IP monetization ● Celyad possesses broad IP estate around allogeneic T-cell technologies and will prioritize IP monetization: o Based on substantial market value of CAR T-cell and increased development of allogeneic t

  15. Slide 15: Thank you

    Thank you @c elyad Oncology 15

Celyad Oncology — Investor Presentation (January 2023) on 6ix